Tag: AML

ncRNA | Free Full-Text | Small Nucleolar (Sno)RNA: Therapy Lays in Translation

2.1. Specificity SnoRNAs are ubiquitous and highly abundant RNAs [21,28]. So, how can one target the malignant cell with little to no harm to healthy cells? Recent publications have demonstrated that some rRNA modifications occur in sub-stoichiometric levels [10,29]. This finding has overturned the notion that all rRNA modifications are…

Continue Reading ncRNA | Free Full-Text | Small Nucleolar (Sno)RNA: Therapy Lays in Translation

Assessing Methylation-Based Sequencing as a Risk-Stratifying Tool in MDS

Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes (MDS), according to a study presented at the 2023 American Society of Clinical Oncology Annual Meeting. “MDS risk stratification is key for [making] optimal treatment decisions. DNA methylation is associated with MDS biology due to frequent somatic mutations…

Continue Reading Assessing Methylation-Based Sequencing as a Risk-Stratifying Tool in MDS

A familial SAMD9 variant present in pediatric myelodysplastic syndrome

Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…

Continue Reading A familial SAMD9 variant present in pediatric myelodysplastic syndrome

Abnormal ressource usage with PyTorch’s DataLoader and as_mount

I see no post about this problem but I have a training speed issue using as_mount for the Blob Storage with DataLoader in PyTorch. The job is just downloading images (by batches only used once) from the blob (by mounting it : data = datastore.path(“./”).as_mount()) and training a neural net…

Continue Reading Abnormal ressource usage with PyTorch’s DataLoader and as_mount

Invivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detection

Invivoscribe and Complete Genomics said Friday that they are partnering to develop and commercialize biomarker tests. Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics’ next-generation sequencing (NGS) platforms….

Continue Reading Invivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detection

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

SAN DIEGO and SAN JOSE, Calif. , June 2, 2023 /PRNewswire/ — Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms. The territory is worldwide, and the field is oncology and cancer research. Under the terms…

Continue Reading Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Blood Test Detects Residual Disease For Adults With AML in Remission Prior to Bone Marrow Transplant

In 2020, there were more than 73,000 people living with acute myeloid leukemia (AML) in the United States. Approximately 31% of those with AML are estimated to survive 5 or more years after their diagnosis.1 Although a bone marrow transplant may increase that 5-year survival rate, the efficacy of the…

Continue Reading Blood Test Detects Residual Disease For Adults With AML in Remission Prior to Bone Marrow Transplant

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan APAC – English USA – English

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be…

Continue Reading Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan APAC – English USA – English

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan, Business News

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may…

Continue Reading Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan, Business News

2023-05-25 | NYSE:BMY | Press Release

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program,show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent hemoglobin increase vs. epoetin alfa, including in clinically relevant subgroups Reblozyl demonstrated a durable response, with nearly 2.5 years median transfusion independence, 1 year…

Continue Reading 2023-05-25 | NYSE:BMY | Press Release

SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

/EIN News/ — NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for…

Continue Reading SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

SELLAS Life Sciences to Present Phase 3 REGAL Trial in

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for the Phase 3…

Continue Reading SELLAS Life Sciences to Present Phase 3 REGAL Trial in

Voruciclib/Venetoclax Shows Early Disease Control in Acute Myeloid Leukemia

Treatment with voruciclib both with and without venetoclax (Venclexta) appears to be tolerable and efficacious for patients with relapsed/refractory acute myeloid leukemia (AML) and B-cell malignancies, according to a press release by MEI Pharma on early findings from a phase 1 study (NCT03547115). Voruciclib is an oral CDK9 inhibitor, hypothesized…

Continue Reading Voruciclib/Venetoclax Shows Early Disease Control in Acute Myeloid Leukemia

Unmet Needs in Diffuse Large B-Cell Lymphoma

Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned,…

Continue Reading Unmet Needs in Diffuse Large B-Cell Lymphoma

NK Cell Therapy Pipeline Insight

PRESS RELEASE Published May 24, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Insight

The roles and implications of RNA m6A modification in cancer

Huang, H., Weng, H. & Chen, J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell 37, 270–288 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  Qing, Y., Su, R. & Chen, J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood 138,…

Continue Reading The roles and implications of RNA m6A modification in cancer

Pre-Transplant DNA Sequencing Suggests Association Between Persistence of Most-Common AML Variants and Poorer Outcomes in Patients with AML

Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia. Detection by DNA sequencing of persistent FLT3-ITD or NPM1 variants – the two most common AML variants – in blood ahead of allogeneic hematopoietic cell transplantation (allo-HCT)…

Continue Reading Pre-Transplant DNA Sequencing Suggests Association Between Persistence of Most-Common AML Variants and Poorer Outcomes in Patients with AML

SC-DARIC33 Demonstrates Potential Next-Generation Approach in AML

Image Credit: © AkuAku [stock.adove.com] Infusions of SC-DARIC33, a chimeric antigen receptor (CAR) T-cell therapy, were well tolerated and did not show dose-limiting toxicities in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from the preliminary correlative analysis of the ongoing phase 1 PLAT-08 trial (NCT05105152).1…

Continue Reading SC-DARIC33 Demonstrates Potential Next-Generation Approach in AML

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Senti Biosciences, Inc. Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies…

Continue Reading Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma

The combination of rituximab (Rituxan), bendamustine (Bendeka), and low-dose cytarabine (R-BAC) without maintenance therapy maintained clinical efficacy after longer follow-up in a cohort of elderly patients with previously untreated mantle cell lymphoma (MCL), according to new findings from the phase 2 RBAC500 clinical trial (NCT01662050) published recently in Blood Advances….

Continue Reading Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma

GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023

GILEAD  AND  KITE  ONCOLOGY  TO  SHOWCASE  ADVANCES  ACROSS  THE  PIPELINE  AIMING  TO  ADDRESS  UNMET  NEEDS  IN  CANCER  CARE  AT  ASCO  2023 – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Haematologic, Genitourinary, Gastrointestinal, Gynaecological and Other Solid Tumours –   –…

Continue Reading GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023

Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas

HOUSTON, May 16, 2023 /PRNewswire/ — Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced today its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas. The first patient has been enrolled to…

Continue Reading Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas

Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval.

150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2nd, 3rd, or 4th salvage of AML and the 1st interim…

Continue Reading Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval.

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Test

69 11.05.2023 – 16:59 Invivoscribe, Inc. San Diego (ots/PRNewswire) SAN DIEGO, May 11, 2023 /PRNewswire/– “We are pleased to announce today that the LeukoStrat® CDx flt3 -Invivoscribe’s mutation test has been approved by BSI (Netherlands) and EMA as a Class C CDx test that meets the stringent new IVDR requirements…

Continue Reading Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Test

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

SAN DIEGO, May 11, 2023 /PRNewswire/ — “Today we are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI (Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one of the first companies…

Continue Reading Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

Senti Bio Announces First Quarter 2023 Results and Pipeline

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform…

Continue Reading Senti Bio Announces First Quarter 2023 Results and Pipeline

Active Research on Uproleselan in Acute Myeloid Leukemia

Brian A. Jonas, MD, associate professor of medicine at UC Davis Health in Sacramento, California, discusses studies investigating the use of uproleselan for the treatment of patients with acute myeloid leukemia (AML). Transcript: 0:08 | been a drug developed to target the e-selectin ligand interaction, it’s a so-called e-selecting antagonist and…

Continue Reading Active Research on Uproleselan in Acute Myeloid Leukemia

python – Why does my training confusion matrix in h2o AutoML only shows 10k total cases instead of 200k

I am currently using h2o autoML to train a model on a binary classification problem. I have a train (70% ~200k rows), valid (10% ~30k rows), test (10% ~30k rows) and blend (10% ~30k rows) datasets all coming from the time sensitive splitting of the original dataset (~300k rows). When…

Continue Reading python – Why does my training confusion matrix in h2o AutoML only shows 10k total cases instead of 200k

Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation | Clinical Epigenetics

5-Azacytidine pretreatment resensitizes cisplatin-resistant DLBCL cell lines to cisplatin to varying degrees A platinum-based anti-neoplastic agent is an essential component of salvage regimens for aggressive lymphomas, for example, rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) for relapsed/refractory DLBCL and Hodgkin lymphoma [21]. As a single agent in humans, cisplatin is administered…

Continue Reading Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation | Clinical Epigenetics

Biomea Fusion Reports First Quarter 2023 Financial Results

Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes Continued enrolling four liquid tumor cohorts in ongoing Phase I…

Continue Reading Biomea Fusion Reports First Quarter 2023 Financial Results

Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML

Dr Eirini Papapetrou speaks to ecancer about her study which found that patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukaemia. This study created a reprogramming method called “Complete Capture of Mutational Burden” (CCoMB). This method combines comprehensive genetic characterisation of the starting sample…

Continue Reading Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML

Applications of single-cell RNA sequencing in drug discovery and development

DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016). Article  PubMed  Google Scholar  Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to…

Continue Reading Applications of single-cell RNA sequencing in drug discovery and development

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results

NEW YORK – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (‘Actinium’ or the ‘Company’), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow…

Continue Reading Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results

Uproleselan Combinations Contribute to Robust Investigational Profile in AML

Michael Andreeff, MD, PhD The E-selectin inhibitor uproleselan (GMI-1271) has shown preliminary efficacy in patients with acute myeloid leukemia (AML), and E-selectin could represent one of several novel targets for treatment of this patient population, according to Michael Andreeff, MD, PhD. Previously, a phase 1/2 trial (NCT02306291) investigating uproleselan plus…

Continue Reading Uproleselan Combinations Contribute to Robust Investigational Profile in AML

2023-04-27 | NYSEAM:ATNM | Press Release

– EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. – Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…

Continue Reading 2023-04-27 | NYSEAM:ATNM | Press Release

Actinium Pharma (ATNM) Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3…

Continue Reading Actinium Pharma (ATNM) Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

–  EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. –  Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…

Continue Reading Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

Actinium Pharma Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation

Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow Transplantation (EBMT)…

Continue Reading Actinium Pharma Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation

Ceftriaxone resistant Salmonella enterica serovar Paratyphi A identified in a case of enteric fever: first case report from Pakistan | BMC Infectious Diseases

Typhoid GBD, Paratyphoid C. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81. Article  Google Scholar  Arndt MB, Mosites EM, Tian M, Forouzanfar MH, Mokhdad AH, Meller M, Ochiai RL, Walson JL. Estimating the burden of…

Continue Reading Ceftriaxone resistant Salmonella enterica serovar Paratyphi A identified in a case of enteric fever: first case report from Pakistan | BMC Infectious Diseases

FDA Extends Review Period for Quizartinib for Adults With FLT3-ITD-Positive AML

Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML), an aggressive form of the blood cancer. Daiichi Sankyo…

Continue Reading FDA Extends Review Period for Quizartinib for Adults With FLT3-ITD-Positive AML

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational trial (ClinicalTrials.gov Identifier: NCT05709093) in China for patients with higher-risk myelodysplastic syndrome…

Continue Reading I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

IDMC Recommends Continuation of REGAL Trial of Galinpepimut-S in AML

Angelos Stergiou, MD, ScD hc An independent data monitoring committee (IDMC) has recommended that the phase 3 REGAL trial (NCT04229979) examining galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) continue as planned without modifications.1 The recommendation follows a positive prespecified risk-benefit assessment of unblinded data from the study. The…

Continue Reading IDMC Recommends Continuation of REGAL Trial of Galinpepimut-S in AML

NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain

PRESS RELEASE Published April 18, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain

Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia

doi: 10.1158/2643-3230.BCD-22-0167. Online ahead of print. Andriana G Kotini #  1   2   3   4 , Saul Carcamo #  1   5 , Nataly Cruz-Rodriguez #  1   2   3   4 , Malgorzata Olszewska  1   2   3   4 , Tiansu Wang  1   2   3   4 , Deniz Demircioglu …

Continue Reading Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting Details Category: DNA RNA and Cells Published on Tuesday, 18 April 2023 10:14 Hits: 247 — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML…

Continue Reading Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells

Positive Results for SELLAS Life Sciences Phase 3 REGAL Study for GalinpepimutS in AML

SELLAS Life Sciences Group, Inc. has announced that the Independent Data Monitoring Committee (IDMC) overseeing the Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) has given the green light for the trial to continue as planned without modifications. This is a positive development for the company,…

Continue Reading Positive Results for SELLAS Life Sciences Phase 3 REGAL Study for GalinpepimutS in AML

Human Acute Myeloid Leukemia Reportedly Closely Mimicked for First Time by Transformative Models

Tisch Cancer Center scientists report that they have developed novel models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a “transformative resource” to study this cancer and eventually its drug response and drug resistance, according to research presented at the annual meeting of the American Association of Cancer…

Continue Reading Human Acute Myeloid Leukemia Reportedly Closely Mimicked for First Time by Transformative Models

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

Caribou Biosciences, Inc. — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models — — CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 — BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a…

Continue Reading Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

Senti Bio to Participate in Upcoming Investor Conferences

Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences: Bank of America 2023 Global Healthcare…

Continue Reading Senti Bio to Participate in Upcoming Investor Conferences

Abstract LB130: Single-cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy | Cancer Research

Epigenetic alterations, such as DNA methylation aberrations, are a hallmark of human cancer. This observation has led to the assessment of hypomethylating agents (HMAs) as potential drugs to treat oncological patients, being considered the clinical approval of these pharmacological compounds in the therapy of myeloid malignancies as one of the…

Continue Reading Abstract LB130: Single-cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy | Cancer Research

Function Oncology Launches With $28M, Seeks to Transform Precision Oncology With CRISPR

NEW YORK – Function Oncology launched on Wednesday with $28 million in recently raised Series A funds and a CRISPR-Cas9 platform, which it hopes will help oncologists tailor patients’ treatments based on the function of their individual cancer genes. The San Diego-based firm is unveiling the first validation data of…

Continue Reading Function Oncology Launches With $28M, Seeks to Transform Precision Oncology With CRISPR

Automated Machine Learning with Python: A Case Study

Image by Author   In today’s world, all organizations want to use Machine learning to analyze the data they generate daily from the users. With the help of a machine or deep learning algorithms, they can analyze the data. Afterwards, they can make the prediction of testing data in the…

Continue Reading Automated Machine Learning with Python: A Case Study

Pacylex Pharmaceuticals Selected as One of Sixteen Canadian Startup Companies to Present at Sweet Biopharma Day 2023

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Edmonton, Alberta, Canada/April 10, 2023- Pacylex Pharmaceuticals today announced it will be presenting at two exclusive life science startup events in Canada in April, spotlighting its emergence as one of the premier…

Continue Reading Pacylex Pharmaceuticals Selected as One of Sixteen Canadian Startup Companies to Present at Sweet Biopharma Day 2023

DNA Sequencing Testing Used to Detect Residual AML Prior to Transplant

The use of high sensitivity DNA sequencing tests to measure residual disease in AML could improve identification of patients at risk for relapse or death. “In acute myeloid leukemia (AML), the association between measurable residual disease (MRD)—leukemic cells remaining in a patient during clinical remission but not detectable by standard…

Continue Reading DNA Sequencing Testing Used to Detect Residual AML Prior to Transplant

Targeting Oncogenic Fusions to Combat Pediatric Cancer Cells

Computational biologists at St. Jude categorized and identified the mechanism underlying oncogenic fusions in pediatric cancer cells. The researchers showed in mice that targeting oncogenic fusions that drive cancer with genome editing tools such as CRISPR has the potential to cure certain tumors. The findings were published in Nature Communications in…

Continue Reading Targeting Oncogenic Fusions to Combat Pediatric Cancer Cells

DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes

In patients with acute myeloid leukemia (AML) in first remission, the persistence of certain DNA variants related to measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplant (HCT) was associated with post-HCT relapse and worse survival outcomes in a recent study. The findings, published in JAMA, suggest that the…

Continue Reading DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes

High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias

Nanopore reads coupled to a novel computational method extends analyses of differential methylation to sparse CpGs (outside CpG islands) We analyzed tumor samples at diagnosis (T) and relapse (R) from three AML patients (UD5, UD10 and AML2) who received standard chemotherapy and relapsed with chemoresistant disease (supplementary Table 1). DNA from…

Continue Reading High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias

Noncatalytic regulation of 18S rRNA methyltransferase DIMT1 in acute myeloid leukemia

Yulia Gonskikh1,6, Julian Stoute1,2,6, Hui Shen1,6, Krista Budinich3,4,5, Bianca Pingul1,2, Kollin Schultz1,2, Heidi Elashal1,2, Ronen Marmorstein1,2, Junwei Shi3,4,5 and Kathy Fange Liu1,2 1Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; 2Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University…

Continue Reading Noncatalytic regulation of 18S rRNA methyltransferase DIMT1 in acute myeloid leukemia

St. Jude computational biologists characterize the full spectrum of oncogenic fusions in pediatric cancer

The scientific foundation needed to work on curing a class of cancer-causing mutations is here, in the form of a tool from St. Jude Children’s Research Hospital. Computational biologists at St. Jude comprehensively categorized and identified the mechanism underlying oncogenic fusions in pediatric cancer cells. Oncogenic fusions are mutations that…

Continue Reading St. Jude computational biologists characterize the full spectrum of oncogenic fusions in pediatric cancer

Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia

FG spectrum in pediatric AML patients A combinatorial approach, including conventional and next-generation sequencing (NGS)-based assays, was employed to profile the FG landscape (see Methods). FG analysis was feasible for 138 patients (94% of the entire cohort, Supplementary Data 1) from whom suitable testing materials were available. The most common FGs…

Continue Reading Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia

CRISPR & Cas Genes Market Will Registered 17.03% Growth Globally

The CRISPR & Cas Genes market growth is driven by increasing number of clinical trials associates with CRIPR technology and rising of development of novel technologies. The CRISPR & Cas genes market revenue will reach at USD 8.96 billion by 2030 with a CAGR of around 17.03% from 2022 to…

Continue Reading CRISPR & Cas Genes Market Will Registered 17.03% Growth Globally

Postdoctoral Fellow – Leukemia (computational/bioinformatics) job with University of Texas MD Anderson Cancer Center

We are seeking a Postdoctoral Fellow with computational/bioinformatics background to work on functional and immunogenomic profiling focusing on leukemia. Our lab conducts single cell, bulk, spatial and CRISPR profiling of AML and immune cells. Our goal is to apply innovative functional genomics, immunogenomics, and bioinformatics approaches to better understand leukemogenesis,…

Continue Reading Postdoctoral Fellow – Leukemia (computational/bioinformatics) job with University of Texas MD Anderson Cancer Center

Advance on engineering of bacteriophages

Introduction Bacteriophage (phage) is a class of widespread viruses exclusively infecting bacteria, playing a key role in ecosystems.1–3 Since phages were discovered over a hundred years ago, many techniques and reagents, such as DNA polymerase, restriction endonuclease, ligase, and CRISPR/Cas system, have been developed from phages, which have together accelerated…

Continue Reading Advance on engineering of bacteriophages

Research Assistant/Research Associate in Inflammation and Computational Biology job with KINGS COLLEGE LONDON

Job description This is an exciting opportunity to be a key member of a team that is researching the genomic origins of inflammatory disease and myeloid cancers.  We are studying clonal haematopoiesis or CHIP, where individuals acquire mutations in blood cells without apparent blood disease, and these mutations occur in…

Continue Reading Research Assistant/Research Associate in Inflammation and Computational Biology job with KINGS COLLEGE LONDON

As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting

Illumina is releasing a new cloud-based, customizable platform that enables tertiary analysis for clinical NGS data, which the company says will streamline interpretation and reporting for a diverse range of application areas. Through application programming interface (API)-based calls, the platform will allow labs to scale up their NGS applications and…

Continue Reading As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting

Dual target therapy reduces DLBCL recurrence

Dual target therapy reduces DLBCL recurrence Non-Hodgkin’s lymphoma is one of the ten most common cancers in Hong Kong, and diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for about 30% to 40% of cancers. Although the traditional treatment has achieved good results in the past 20…

Continue Reading Dual target therapy reduces DLBCL recurrence

Biomea Fusion Reports Fourth Quarter and Full Year 2022

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials COVALENT-101 (Phase I study) enrolling four liquid tumor cohorts, each focused on distinct patient subsets of acute lymphocytic and…

Continue Reading Biomea Fusion Reports Fourth Quarter and Full Year 2022

100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment

PRESS RELEASE Published March 23, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading 100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment

Creating sample groups from a combination of genes for survival analysis

This is the post/tutorial where Dr Kevin Blighe showed how to perform survival analysis with gene here in this he showed how to use single gene as predictor and create groups based on expression and classify them as mid or high or low. Now How to do the same with…

Continue Reading Creating sample groups from a combination of genes for survival analysis

FDA Grants Orphan Drug Designation to EP0042 for AML

The FDA has granted orphan drug designation to the investigational dual FLT-3 and Aurora kinase inhibitor EP0042 for the treatment of pretreated acute myeloid leukemia (AML), according to a press release from Ellipses Pharma.1 “The designation is an important milestone in the development of EP0042 and underscores the work we…

Continue Reading FDA Grants Orphan Drug Designation to EP0042 for AML

10 immunotherapy companies making waves in 2023

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses….

Continue Reading 10 immunotherapy companies making waves in 2023

Bea Stollnitz – Training and deploying your PyTorch model in the cloud with Azure ML

Introduction You’ve been training your PyTorch models on your machine, and getting by just fine. Why would you want to train and deploy them in the cloud? Training in the cloud will allow you to handle larger ML models and datasets than you could train on your development machine. And…

Continue Reading Bea Stollnitz – Training and deploying your PyTorch model in the cloud with Azure ML

Astellas menopause study meets endpoints, leukemia drug doesn’t

There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment…

Continue Reading Astellas menopause study meets endpoints, leukemia drug doesn’t

Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing

. 2023 Feb 22;15(5):1386. doi: 10.3390/cancers15051386. Affiliations Expand Affiliations 1 Department of Haematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia. 2 Clinical Haematology Referral Laboratory, Haematology Department, Hospital Ampang, Ministry of Health Malaysia, Ampang 68000, Malaysia. 3 Department of Biomedical Science, College of Health…

Continue Reading Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing

Scientists identify the cause of leukemia in people with trisomy 21

People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing Acute Myeloid Leukaemia (AML), an aggressive form of blood cancer. Scientists led by the Department of Paediatrics at University Hospital Frankfurt have now identified the cause: although the additional chromosome 21 leads…

Continue Reading Scientists identify the cause of leukemia in people with trisomy 21

Caribou Biosciences Reports Fourth Quarter and Full Year

— CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 — — CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 — — CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 — — $317.0…

Continue Reading Caribou Biosciences Reports Fourth Quarter and Full Year

QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

QIAGEN N.V.QGEN recently announced that it has entered into a strategic partnership with Servier. The agreement is intended to develop a companion diagnostic test for TIBSOVO — an isocitrate dehydrogenase-1 or IDH1 inhibitor indicated for treating the blood cancer acute myeloid leukemia or AML. For investors’ note, QIAGEN has master…

Continue Reading QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

GDCquery error downloading TARGET-AML data

Hello there, I’m trying to download TARGET-AML data via GDCquery: library(TCGAbiolinks) query_target <- GDCquery(project = “TARGET-AML”, data.category = “Transcriptome Profiling”, data.type = “Gene Expression Quantification”, workflow.type = “STAR – Counts”) And I got this error: Warning messages: 1: In open.connection(con, “rb”) : URL ‘https://api.gdc.cancer.gov/files/?pretty=true&expand=cases,cases.samples.portions.analytes.aliquots,cases.project,center,analysis,cases.samples&size=10246&filters=%7B%22op%22:%22and%22,%22content%22:[%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:[%22TARGET-AML%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.data_category%22,%22value%22:[%22Transcriptome%20Profiling%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.data_type%22,%22value%22:[%22Gene%20Expression%20Quantification%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.analysis.workflow_type%22,%22value%22:[%22STAR%20-%20Counts%22]%7D%7D]%7D&format=JSON’: Timeout of 60 seconds was reached…

Continue Reading GDCquery error downloading TARGET-AML data

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…

Continue Reading Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant

NEW YORK – Using DNA sequencing to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) patients about to undergo a stem cell transplant can help predict who will have their disease recur, according to a new study by researchers at the US National Heart, Lung, and Blood Institute…

Continue Reading Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant

Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

TOKYO and ROCKVILLE, Md., March 9, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following…

Continue Reading Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

MD Anderson Research Highlights for March 8,

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include…

Continue Reading MD Anderson Research Highlights for March 8,

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized. Objective: To determine whether DNA sequencing to…

Continue Reading DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant

News Release Tuesday, March 7, 2023 A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return. Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute…

Continue Reading Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant

Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM

Incidence of certain second primary malignancies (SPMs) were associated with increased overall survival (OS) among patients with multiple myeloma (MM), according to abstract findings presented at the 64th American Society of Hematology Meeting and Exposition.1 There is significant literature regarding the incidence of SPMs in patients with MM, in which…

Continue Reading Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM

Mutated Cohesin Throws DNA Splicing out of Whack, Resulting in Cancer

The protein complex cohesin is fundamental to the cell division process, as it holds sister chromatids tightly together in a ringlike structure before a cell physically splits. But now researchers at the National Cancer Institute (NCI) have uncovered that the protein complex has another function, too—one that can answer questions…

Continue Reading Mutated Cohesin Throws DNA Splicing out of Whack, Resulting in Cancer

Actinium Pharma to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B By Investing.com

Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar at 8 a.m. EST on Tuesday, February 28, 2023, to discuss the results from the recently completed pivotal Phase…

Continue Reading Actinium Pharma to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B By Investing.com

Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant

Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that it received clearance from the Pharmaceuticals and Medical Devices…

Continue Reading Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant

Priothera cleared to begin Japanese arm of pivotal Phase 3

Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that it received clearance from the Pharmaceuticals and Medical Devices…

Continue Reading Priothera cleared to begin Japanese arm of pivotal Phase 3

DLBCL therapeutic strategies and gene-oriented treatment

Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….

Continue Reading DLBCL therapeutic strategies and gene-oriented treatment

INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

Our management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and…

Continue Reading INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

New promising targeted drug for a rare leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone.  Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing…

Continue Reading New promising targeted drug for a rare leukemia

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic…

Continue Reading Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

PRESS RELEASE Published February 21, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

Early Data for Orca-T Cellular Therapy Provides Basis for Phase 3 Study in AML

The use of the precision cellular therapy Orca-T demonstrated promising efficacy effects at a median follow-up of 1 year in patients with acute leukemia or high-risk myelodysplastic syndrome (MDS) in an early analysis of a phase 1b and 2 study that have yet to be reported, according to data presented…

Continue Reading Early Data for Orca-T Cellular Therapy Provides Basis for Phase 3 Study in AML

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

–  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm –  In patients achieving 6-month dCR with Iomab-b,…

Continue Reading Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

Pfizer Announces Positive TALZENNA and XTANDI Combination Data from Phase 3 TALAPRO-2 Study

NEW YORK – Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared to placebo plus XTANDI in men with metastatic…

Continue Reading Pfizer Announces Positive TALZENNA and XTANDI Combination Data from Phase 3 TALAPRO-2 Study

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML

ROCKVILLE, Md – GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the independent Data Monitoring Committee (DMC) reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) and recommended the study should continue to the originally planned final overall survival event trigger. ‘We…

Continue Reading GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML

Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger

An independent data monitoring committee (IDMC) has recommended that a phase 3 trial (NCT03616470) evaluating uproleselan (GMI-1271) plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia (AML) should continue to the planned overall survival (OS) event trigger.1 The IDMC conducted an interim utility analysis using a very high statistical threshold…

Continue Reading Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger